US10047067B2 - Composition for treating kidney disease comprising pyrazole derivative - Google Patents

Composition for treating kidney disease comprising pyrazole derivative Download PDF

Info

Publication number
US10047067B2
US10047067B2 US14/424,771 US201314424771A US10047067B2 US 10047067 B2 US10047067 B2 US 10047067B2 US 201314424771 A US201314424771 A US 201314424771A US 10047067 B2 US10047067 B2 US 10047067B2
Authority
US
United States
Prior art keywords
pyrazol
pyridin
compound
acid
kidney disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US14/424,771
Other languages
English (en)
Other versions
US20150218125A1 (en
Inventor
Yun Soo Bae
Hun Joo Ha
Kee In Lee
Kyung Hee Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ewha Womans University
Original Assignee
Ewha Womans University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ewha Womans University filed Critical Ewha Womans University
Assigned to EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION reassignment EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HA, HUN JOO, SONG, KYUNG HEE, BAE, YUN SOO, LEE, KEE IN
Publication of US20150218125A1 publication Critical patent/US20150218125A1/en
Application granted granted Critical
Publication of US10047067B2 publication Critical patent/US10047067B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to a composition for the prevention or treatment of kidney disease, comprising a pyrazole derivative.
  • kidney disease Patients with chronic kidney disease (CKD) are at 10-fold higher risk of cardiovascular disease incidence and mortality than an age control group, and have recently increased in a geometric progression (Schieppati A, Remuzzi G: Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl. 98:S7-S10, 2005(1)).
  • CKD is characterized by epithelial-to-mesenchymal transition (EMT) and accumulation of extracellular matrix (ECM) proteins, and exhibits various pathological traits including basement membrane thickening of glomerular capillaries, glomerular mesangial expansion, renal tubular interstitial fibrosis, glomerular hypertrophy and nephromegaly, and proteinuria.
  • EMT epithelial-to-mesenchymal transition
  • ECM extracellular matrix
  • TGF- ⁇ 1 Transforming growth factor- ⁇ 1 (TGF- ⁇ 1), a factor implicated in renal fibrosis, serves as a final mediator in the production of extracellular matrix proteins in response to various stimuli and thus is regarded as a fibrosis indicator (Qian Y, Feldman E, Pennathur S, Kretzler M, Brosius F C 3rd: From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes. 57: 1439-45, 2008).
  • Diabetic kidney disease which is a kind of CKD, is the most common cause of end-stage renal disease (ESRD) (U.S. Renal Data System, USRDS 2011 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md., 2011).
  • ESRD end-stage renal disease
  • Treatment modalities, known thus far, for restraining the progression of CKD including DKD to end-stage renal disease include the throughgoing control of blood pressure and the use of renin-angiotensin system (RAS) blocker, but there is still a need for a therapeutic agent that guarantees perfect nephroprotective effect (Zhang M Z, Wang S, Yang S, Yang H, Fan X, Takahashi T, Harris R C: The Role of Blood Pressure and the Renin-Angiotensin System in Development of Diabetic Nephropathy (DN) in eNOS ⁇ / ⁇ db/db Mice. Am J Physiol Renal Physiol. Epub ahead of print, 2011).
  • DN Diabetic Nephropathy
  • the present invention provides a composition for the prevention or treatment of kidney disease, comprising a compound selected from among the following compounds, or a pharmaceutically acceptable salt thereof:
  • the present invention provides a composition for the prevention or treatment of kidney disease, comprising a compound selected among from the following compounds, or a pharmaceutically acceptable salt thereof:
  • the term “pharmaceutically acceptable salt” refers to a salt typically used in the medicinal field.
  • the pharmaceutically acceptable salt include inorganic acid salts prepared from, for example, hydrochloride, nitric acid, phosphoric acid, bromic acid, iodic acid, perchloric acid, stanic acid, and sulfuric acid, organic acid salts prepared from, for example, acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanilic acid, hydroiodic acid, etc., and sulfonates prepared from, for example, methane sulfonic acid, ethane sul
  • the kidney disease may include diabetic kidney disease, hypertensive nephropathy, glomerulonephritis, pyelonephritis, interstitial nephritis, lupus nephritis, polycystic kidney disease or renal failure.
  • the kidney disease may be characterized by proteinuria, glomerular sclerosis, or renal interstitial fibrosis.
  • composition of the present invention may further comprise a pharmaceutically acceptable additive such as a diluent, a binder, a disintegrant, a lubricant, a pH-adjusting agent, an antioxidant, a solubilizer, etc.
  • a pharmaceutically acceptable additive such as a diluent, a binder, a disintegrant, a lubricant, a pH-adjusting agent, an antioxidant, a solubilizer, etc.
  • sugar, starch, microcrystalline cellulose, lactose (lactose hydrate), glucose, D-mannitol, alginate, alkaline earth metal salts, clay, polyethylene glycol, anhydrous calcium hydrogen phosphate, or a combination thereof may be used.
  • binder starch, microcrystalline cellulose, highly dispersable silica, mannitol, D-mannitol, sucrose, lactose hydrate, polyethylene glycol, polyvinylpyrrolidone (Povidone), polyvinylpyrrolidone copolymer (copovidone), hypromellose, hydroxypropyl cellulose, natural gum, synthetic gum, copovidone, gelatin, or a combination thereof may be used.
  • ovidone polyvinylpyrrolidone
  • copovidone polyvinylpyrrolidone copolymer
  • hypromellose hypromellose
  • hydroxypropyl cellulose natural gum, synthetic gum, copovidone, gelatin, or a combination thereof
  • starch or modified starch such as sodium starch glycolate, corn starch, potato starch, pregelatinized starch, etc.; clay such as bentonite, montmorillonite, veegum, etc.; celluloses such as microcrystalline cellulose, hydroxypropyl cellulose, carboxymethyl cellulose; alginic acid or a salt thereof such as sodium alginate; crosslinked celluloses such as croscarmellose sodium; gums such as guar gum, xanthan gum, etc.; crosslinked polymers such as crosslinked polyvinyl pyrrolidone (crospovidone), etc.; effervescent agents such as sodium bicarbonate, citric acid, etc., or a combination thereof may be used.
  • clay such as bentonite, montmorillonite, veegum, etc.
  • celluloses such as microcrystalline cellulose, hydroxypropyl cellulose, carboxymethyl cellulose
  • alginic acid or a salt thereof such as sodium alginate
  • talc stearic acid, magnesium stearate, calcium stearate, sodium laurylsulfate, hydrogenated vegetable oil, sodium benzoate, sodium stearyl fumarate, glyceryl vehenate, glyceryl monooleate, glycerylmonostearate, glyceryl palmitostearate, colloidal silica, or a combination thereof may be used.
  • an acidifier such as acetic acid, adipic acid, ascorbic acid, sodium ascorbate, sodium etherate, malic acid, succinic acid, tartaric acid, fumaric acid, citric acid, etc.
  • an alkalinizer such as precipitated calcium carbonate, ammonia water, meglumin, sodium carbonate, magnesium oxide, magnesium carbonate, sodium citrate, tribasic calcium phosphate, etc., may be used.
  • antioxidant dibutyl hydroxy toluene, butyrated hydroxyanisole, tocopherol acetate, tocopherol, propyl galate, sodium hydrogen sulfite, and sodium pyrosulfite etc.
  • solubilizer sodium lauryl sulfate, polyoxyethylene sorbitan fatty acid ester (such as polysorbate), docusate sodium, poloxamer etc.
  • the composition of the present invention may include an enteric polymer, a water-insoluble polymer, a hydrophobic compound, and a hydrophilic polymer.
  • the enteric polymer refers to a polymer which is insoluble or stable under acidic conditions of less than pH 5 and is dissolved or degraded under specific pH conditions of pH 5 or higher.
  • the enteric polymer may be enteric cellulose derivatives such as hypromellose acetate succinate, hypromellose phthalate (hydroxypropylmethylcellulose phthalate), hydroxymethylethylcellulose phthalate, cellulose acetate phthalate, cellulose acetate succinate, cellulose acetate maleate, cellulose benzoate phthalate, cellulose propionate phthalate, methylcellulose phthalate, carboxymethylethyl cellulose, ethylhydroxyethyl cellulose phthalate, and methyl hydroxyethyl cellulose; enteric acrylic acid copolymers such as a styrene-acrylic acid copolymer, a methyl acrylate-acrylic acid copolymer, a methyl acrylate-methacrylic acid copolymer (e
  • the water-insoluble polymer refers to a pharmaceutically acceptable, water-insoluble polymer that controls the release of a drug.
  • the water-insoluble polymer may be polyvinyl acetate (e.g. Kollicoat SR30D), a water-insoluble polymethacrylate copolymer [for example, poly(ethyl acrylate-methyl methacrylate) copolymer (e.g., Eudragit NE30D), a poly(ethyl acrylate-methyl methacrylate-trimethyl aminoethyl methacrylate) copolymer (e.g., Eudragit RSPO), etc.], ethyl cellulose, cellulose ester, cellulose ether, cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate, etc.
  • the hydrophobic compound refers to a pharmaceutically acceptable, water-insoluble substance that controls the release of a drug.
  • the hydrophobic compound may be fatty acids and fatty acid esters such as glyceryl palmitostearate, glyceryl stearate, glyceryl behenate, cetyl palmitate, glyceryl monooleate and stearic acid; fatty acid alcohols such as cetostearyl alcohol, cetyl alcohol and stearyl alcohol; waxes such as carnauba wax, beeswax and microcrystalline wax; and inorganic substance such as talc, precipitated calcium carbonate, calcium hydrogen phosphate, zinc oxide, titanium oxide, kaolin, bentonite, montmorillonite and veegum.
  • the hydrophilic polymer refers to a pharmaceutically acceptable, water-soluble polymer that controls the release of a drug.
  • the hydrophilic polymer may be saccharides such as dextrin, polydextrin, dextran, pectin and a pectin derivative, alginate, polygalacturonic acid, xylan, arabinoxylan, arabinogalactan, starch, hydroxypropyl starch, amylose and amylopectin; cellulose derivatives such as hypromellose, hydroxypropylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, methylcellulose, and sodium carboxymethylcellulose; gums such as guar gum, locust bean gum, tragacanth, carrageenan, gum acacia, gum arabic, gellan gum and xanthan gum; proteins such as gelatin, casein and zein; polyvinyl derivatives such as polyvinyl alcohol, polyvinylpyrrolidone and polyvinylacetal die
  • Eudragit E100 manufactured by Evonik, Germany
  • a poly(ethyl acrylate-methyl methacrylate-triethylaminoethyl-methacrylate chloride) copolymer e.g. Eudragit RL and RS, manufactured by Evonik, Germany
  • polyethylene derivatives such as polyethylene glycol, and polyethylene oxide
  • carbomer e.g. Eudragit RL and RS
  • composition of the present invention may be formulated with the use of pharmaceutically acceptable additives such as various additives selected from colorants and fragrances.
  • the range of the additive that can be used in the present invention is not limited to the above-mentioned additives, the additive may be appropriately selected by those skilled in the art and the composition may be formulated with the use of the above-mentioned additives in a conventional dose.
  • the pharmaceutical composition in accordance with the present invention may be formulated into oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, medicines for external use, suppositories or sterile injection solutions, using a conventional method, and may be used.
  • oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, medicines for external use, suppositories or sterile injection solutions, using a conventional method, and may be used.
  • the present invention provides a method for preventing or treating kidney disease, comprising administering to a subject including a mammal a composition for the prevention or treatment of kidney disease comprising a compound selected from among the following compounds, or a pharmaceutically acceptable salt thereof:
  • the term “administering” means the introduction of the composition for preventing and treating kidney disease in accordance with the present invention to a patient by any appropriate method. So long as it allows the composition for preventing and treating kidney disease in accordance with the present invention to reach a target tissue, any route via which the composition is administered may be taken.
  • the composition may be administered orally, intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, intranasally, intrapulmonary, rectally, intracavitary, intraperitoneally, or intrathecally, but not limited thereto.
  • composition for preventing or treating kidney diseases in accordance with the present invention may be conducted once a day, or two or more times a day at regular intervals of time.
  • the effective dose level of the compound selected from among the following compounds or a pharmaceutically acceptable salt thereof may vary depending on a variety of factors including the patient's weight, age, gender, general health, and diet, the time of administration, the route of administration, and the rate of excretion, and the severity of disease:
  • dosages may range from 0.1 to 100 mg/kg/day, which may vary depending on the severity of disease, and patient's age, sex, etc.
  • the present invention provides a method for preventing or treating kidney disease, comprising administering to a subject including a mammal a composition for the prevention or treatment of kidney disease comprising a compound selected from among the following compounds, or a pharmaceutically acceptable salt thereof:
  • the present invention provides use of the following compounds or a pharmaceutically acceptable salt thereof in preparing a pharmaceutical formulation for the prevention or treatment of kidney disease:
  • the present invention provides use of the following compounds or a pharmaceutically acceptable salt thereof in preparing a pharmaceutical formulation for the prevention or treatment of kidney disease:
  • the compounds of the present invention can be used in preventing or treating kidney disease.
  • FIG. 1A-C shows the effect of the compound of Example 1 on glomerular hypertrophy and glomerular mesangial expansion.
  • FIG. 2 shows the effect of the compound of Example 1 on collagen accumulation (Masson's trichrome staining, picrosirius red staining), and production of macrophage marker (F4/80).
  • FIG. 3A-E shows the effect of the compound of Example 1 on the expression of transforming growth factor- ⁇ 1 (TGF- ⁇ 1), extracellular matrix proteins (fibronectin, collagen IV, and collagen I ⁇ 1), and inflammatory factor (F4/80).
  • TGF- ⁇ 1 transforming growth factor- ⁇ 1
  • extracellular matrix proteins fibronectin, collagen IV, and collagen I ⁇ 1
  • F4/80 inflammatory factor
  • FIGS. 4 to 13 show the inhibitory effects of compounds of Examples 1 to 9 and Comparative Example 1 on collagen I ⁇ 1 expression in proximal tubular cells.
  • Step 1 Synthesis of 1-(pyridin-2-yl)-3-phenyl-4-propyl-1H-pyrazol-5-ol[1-(pyridin-2-yl)-3-phenyl-4-propyl-1H-pyrazol-5-ol]
  • the compound of Chemical Formula 3 was synthesized as disclosed in Korean Patent No. 10-0942382. Briefly, drops of 2-hydrazinopyridine (1.1 equivalents) in 3 ml of ethanol were slowly added to 3-(3-methoxyphenyl)-3-oxo-propionic acid ethyl ester (1 equivalent) and 4 ml of ethanol at 0° C. in a round-bottom flask. The solution was heated under reflux for 20 minutes. After removal of the solvent by distillation under reduced pressure, the solid thus obtained was washed with hexane and ethyl acetate, and dried in a vacuum to afford the compound of Chemical Formula 3: Yield 67%.
  • the compound of Chemical Formula 3 is an enol form while the compound of Chemical Formula 3′ takes a keto form. These compounds are in keto-enol tautomerism so that they may interconvert to each other.
  • the compound was synthesized as disclosed in Korean Patent Application Publication No. 10-2011-0025149. Briefly, a solution of 2-hydrazinopyridine (10 mmol, manufactured by Aldrich) in ethanol (10 mL) was added to ethyl 4-bromo benzoylacetate (10 mmol, manufactured by Aldrich) and ethanol (10 mL) in a 100 mL round-bottom flask. After stirring at 100° C. for 8 hrs, the solution was cooled at room temperature. The solid thus formed was filtered, washed with ethanol and hexane, and dried in a vacuum to afford the compound of Chemical Formula 4.
  • the compound was synthesized as disclosed in Korean Patent Application Publication No. 10-2011-0025149. Briefly, a solution of 2-hydrazinopyridine (10 mmol, manufactured by Aldrich) in ethanol (10 mL) was added to ethyl 3-iodobenzoylacetate (10 mmol, manufactured by Aldrich) and ethanol (10 mL) in a 100 mL round-bottom flask. After stirring at 100° C. for 8 hrs, the solution was cooled at room temperature. The solid thus formed was filtered, washed with ethanol and hexane, and dried in a vacuum to afford the compound of Chemical Formula 6.
  • Step 1 Synthesis of ethyl 4-(naphthalen-3-yloxy)-3-oxobutanoate
  • the compound of Chemical Formula 8 was synthesized as disclosed in Korean Patent Application Publication No. 10-2011-0025149.
  • the compound of Chemical Formula 9 was synthesized as disclosed in Korean Patent Application Publication No. 10-2011-0025149.
  • 1-(pyridin-2-yl)-3-phenyl-4-propyl-1H-pyrazol-5-ol.HCl the compound of Example 1 was orally administered to the mice at a dose of 10 mg/kg/day for 12 weeks. After 12 weeks of administration, they were sacrificed, and blood samples therefrom were measured for levels of blood glucose, hemoglobin A1c (HbA1c), and plasma creatinine. For urine protein levels, urine samples were taken. The urine protein levels were measured.
  • the control stands for a group in which type 1 diabetes mellitus was not induced, the diabetes group (DM) for a group in which type 1 diabetes mellitus was induced, and the treatment group (DM+compound of Example 1) for a group that was treated with the compound of Example 1 after introduction of type 1 diabetes mellitus.
  • the diabetes group decreased in body weight and increased in blood glucose level and hemoglobin A1c level, compared to the control (WT), which indicated that the diabetes group maintained hyperglycemia for 12 weeks after the introduction of type 1 diabetes mellitus.
  • the diabetes group was found to increase in kidney weight and ratio of kidney weight to body weight, as well, hypertrophy was caused in the diabetes group.
  • the diabetes group increased in an excretion level of albumin, although not different in plasma creatinine compared to the control.
  • mice to which 1-(pyridin-2-yl)-3-phenyl-4-propyl-1H-pyrazol-5-ol.HCl, the compound of Example 1, was administered after the induction of diabetes mellitus (treatment group) exhibited no significant differences in body weight, blood glucose, hemoglobin A1c, kidney weight, kidney weight/body weight, and plasma creatinine, compared to the diabetes group, but decreased in urine albumin.
  • the compound of the present invention (1-(pyridin-2-yl)-3-phenyl-4-propyl-1H-pyrazol-5-ol.HCl) was found to have a nephroprotective effect as it decreased the diabetic kidney disease-caused proteinuria (excretion of albumin, etc.).
  • mice As described in Example 10, diabetes was induced in mice that were then treated with 1-(pyridin-2-yl)-3-phenyl-4-propyl-1H-pyrazol-5-ol.HCl, the compound of Example 1, and scarified 12 weeks later. After cardiac perfusion with 0.1 M PBS (phosphate-buffered saline), tissue fixation was performed overnight with 2% PLP (paraformaldehyde-lysine-periodate).
  • PBS phosphate-buffered saline
  • Paraffin embedding was conducted as follows: sequential treatment with: 70% ethanol for 1 hr; 80% ethanol for 1 hr; 90% ethanol for 1 hr; 95% ethanol for 1 hr, twice; 100% ethanol for 1 hr, three times; xylene for 30 min, twice; paraffin for 30 min; and paraffin for 1.5 hrs.
  • the paraffin tissue was sliced into a section 4 ⁇ m thick, followed by PAS (periodic acid-Schiff) staining to detect basement membranes and glycogen deposition.
  • PAS peripheral acid-Schiff
  • FIG. 1 shows images of glomeruli stained with PAS (periodic acid-Schiff) (A), a graph of glomerular volumes (B), and a graph of fractional mesangial areas (C).
  • the control stands for a group in which type 1 diabetes mellitus was not induced
  • the diabetes group DM
  • the treatment group DM+compound of Example 1
  • SE mean ⁇ standard error
  • the glomerular size of the group treated with the compound of Example 1 increased, compared to the control, but significantly smaller than that of the diabetes group, while glomerular mesangial expansion in the treatment group was reduced to the level of the control, compared to the diabetes group.
  • the compounds of the present invention can prevent renal fibrosis by suppressing the renal mesangial and tubulointerstitial accumulation of collagen through down-regulation of the extracellular matrix collagen I ⁇ 1 in proximal tubular cells.
  • the compound of the present invention (1-(pyridin-2-yl)-3-phenyl-4-propyl-1H-pyrazol-5-ol.HCl) was found to have nephroprotective effects by reducing glomerular size and glomerular mesangial expansion in diabetic kidney disease-induced animal models.
  • mice were then treated with 1-(pyridin-2-yl)-3-phenyl-4-propyl-1H-pyrazol-5-ol.HCl, the compound of Example 1, and scarified 12 weeks later.
  • cardiac perfusion with 0.1 M PBS (phosphate-buffered saline)
  • tissue fixation was performed overnight with 2% PLP (paraformaldehyde-lysine-periodate).
  • Paraffin embedding was conducted by sequential treatment with: 70% ethanol for 1 hr; 80% ethanol for 1 hr; 90% ethanol for 1 hr; 95% ethanol for 1 hr, twice; 100% ethanol for 1 hr, three times; xylene for 30 min, twice; paraffin for 30 min; and paraffin for 1.5 hrs.
  • the paraffin tissue was sliced into a section 4 ⁇ m thick, followed by deparaffinization with alcohol.
  • the renal tissue was immersed in 10 mM citrate buffer (pH 6.0), heated with microwaves (at 700 watts for 5 min and then at 100 watts for 5 min), and then finally incubated at room temperature for 30 min Intrinsic peroxidase was removed by treatment with peroxidase blocking reagent (Peroxidase Blocking Reagent Ready-To-Use, Dakocytomation) for 30 min.
  • peroxidase blocking reagent Peroxidase Blocking Reagent Ready-To-Use, Dakocytomation
  • the renal tissue was incubated with a protein block serum-free solution (Protein Blocking Serum-Free Ready-To-Use, Dakocytomation) for 15 min and then overnight with a primary antibody (F4/80, Santa Cruz) at 4° C., followed by amplification with ABC kit (Santa Cruz) using the ABC (avidin-biotin-enzyme complex) method. Color was developed with a liquid DAB substrate chromogen system (Dakocytomation) before observation under an optical microscope.
  • a protein block serum-free solution Protein Blocking Serum-Free Ready-To-Use, Dakocytomation
  • tissue injury staining was performed with Masson's trichrome (Sigma-Aldrich) and picrosirius red (Sigma-Aldrich) according to the manufacturer's instructions. The degree of tissue injury was expressed as tubulointerstitial collagen accumulation per area.
  • results of immunohistochemical staining (IHC F4/80), Masson's trichrome staining, and picrosirius red staining are shown in FIG. 2 .
  • the control stands for a group in which type 1 diabetes mellitus was not induced
  • the diabetes group (DM) for a group in which type 1 diabetes mellitus was induced
  • the treatment group (DM+compound of Example 1) for a group that was treated with the compound of Example 1 after introduction of type 1 diabetes mellitus.
  • the black dots in the IHC F4/80 panels of FIG. 2 represent the expression of F4/80 while collagen accumulation is represented by blue and red colors in the panels of Masson's trichrome and picrosirius red, respectively.
  • FIG. 2 more abundant blue sites were visualized in the diabetes group than in the control as stained with Masson's trichrome.
  • the group treated with the compound of Example 1 was visualized blue by Masson's trichrome staining in a smaller area than was the diabetes group.
  • Picrosirius red staining visualized the diabetes group in red in a larger area, compared to the control while a smaller area of the group treated with the compound of Example 1 was visualized in red, compared to the diabetes group.
  • F4/80 immunohistochemical staining
  • a larger area of the diabetes group was visualized in black, compared to the control.
  • the group treated with the compound of Example 1 was stained in black in a smaller area than was the diabetes group.
  • Masson's trichrome staining and picrosirius red staining both designed to examine extracellular matrix accumulation, indicated greater collagen accumulation in the diabetes group than in the control. Also, more abundant macrophages were detected in the diabetes group than in the control as demonstrated by immunohistochemical staining (F4/80).
  • the administration of the compound of Example 1, 1-(pyridin-2-yl)-3-phenyl-4-propyl-1H-pyrazol-5-ol.HCl significantly reduced collagen accumulation and macrophage production (F4/80).
  • the compound (1-(pyridin-2-yl)-3-phenyl-4-propyl-1H-pyrazol-5-ol.HCl) according to the present invention was found to inhibit collagen accumulation and reduce macrophage (F4.80) production in diabetic kidney disease-induced animal models, thus exhibiting nephroprotective effects.
  • Example 10 diabetes was induced, and 1-(pyridin-2-yl)-3-phenyl-4-propyl-1H-pyrazol-5-ol.HCl, the compound of Example 1 of the present invention, was administered to the mice that were sacrificed 12 weeks later. Then, renal tissues were excised from the mice and homogenized with a predetermined amount (500 ⁇ l) of Trizol reagent (Invitrogen), followed by centrifuging the homogenate (13,000 rpm, 10 min). The supernatant was reacted with 200 ⁇ l of chloroform for 15 min and centrifuged. The total RNA was precipitated with isopropyl alcohol, and washed with 75% ethyl alcohol before use in experiments.
  • Trizol reagent Invitrogen
  • cDNA was synthesized using a reverse transcription kit (Applied Biosystems), and selective mRNA was quantitatively analyzed in ABI 7300 real-time PCR thermal cycler (Applied Biosystems) with the aid of SYBR Green PCR Master Mix kit according to the manufacturer's instruction. Each experiment was run in duplicate with 20 ⁇ l. For correct quantitation and identification of results from a single product, a standard curve and a dissociation curve were employed. PCR was performed with 40 thermal cycles of 95° C. for 15 sec and 56° C. for 1 min. Sets of primers for amplifying genes of interest were synthesized in Bionia (Daejeon, Korea) as shown in Table 2. Real-time PCR results are shown in FIG. 3 .
  • FIG. 3 shows graphs of expression level ratios of TGF- ⁇ 1 mRNA to 18S rRNA (A), expression level ratios of fibronectin mRNA to 18S rRNA (B), expression level ratios of collagen IV mRNA to 18S rRNA (C), expression level ratios of Collagen I ⁇ 1 mRNA to 18S rRNA (D), and expression level ratios of F4/80 mRNA to 18S rRNA (E).
  • A shows graphs of expression level ratios of TGF- ⁇ 1 mRNA to 18S rRNA
  • B expression level ratios of fibronectin mRNA to 18S rRNA
  • C collagen IV mRNA to 18S rRNA
  • D expression level ratios of Collagen I ⁇ 1 mRNA to 18S rRNA
  • E expression level ratios of F4/80 mRNA to 18S rRNA
  • the control stands for a group in which type 1 diabetes mellitus was not induced
  • the diabetes group DM for a group in which type 1 diabetes mellitus was induced
  • the treatment group DM+compound of Example 1 for a group that was treated with the compound of Example 1 after introduction of type 1 diabetes mellitus.
  • Data of FIG. 3 are expressed as mean ⁇ standard error (SE) from 8 to 12 mice per group.
  • SE standard error
  • Statistic comparison among the groups was analyzed by ANOVA and Fisher's least significant difference test, with significance at p ⁇ 0.05. *P ⁇ 0.05 vs. WT, ⁇ P ⁇ 0.05 vs. DM.
  • the diabetes-induced mice to which 1-(pyridin-2-yl)-3-phenyl-4-propyl-1H-pyrazol-5-ol.HCl, the compound of Example 1 of the present invention, was administered (the treatment group of the compound of Example 1) significantly decreased in the expression levels of TGF- ⁇ 1, a factor related to renal fibrosis, and fibronectin, collagen I ⁇ 1, collagen IV, well known as extracellular matrix proteins, and the inflammatory factor F4/80, compared to the diabetes group.
  • the compound (1-(pyridin-2-yl)-3-phenyl-4-propyl-1H-pyrazol-5-ol.HCl) according to the present invention was found to have a nephroprotective effect as it inhibited renal fibrosis.
  • mProx24 which is a name of the proximal tubular cells derived from proximal tubule segments obtained by finely sectioning the kidney of adult C57BL6/J mice, was granted from Professor Sugaya, St. Marianna University School of Medicine, Kanagawa, Japan.
  • mProx24 was cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% fetal calf serum (FCS, Gibco), 100 U/ml penicillin, 100 ⁇ g/ml streptomycin, and 44 mM NaHCO 3 at 37° C. in a 5% CO 2 atmosphere.
  • FCS fetal calf serum
  • the cells were cultured in 6-well plates.
  • a reaction volume of 20 ⁇ L including cDNA transcripts, primer pairs, and SYBR Green PCR Master Mix (Applied Biosystems) was subjected to real-time PCR with the aid of StepOnePlus (Applied Biosystems) (real-time PCR condition: 95° C., 10 min ⁇ 40 thermal cycles of denaturation at 95° C. for 15 sec and primer annealing at 60° C. for 1 min ⁇ 95° C. for 15 sec, 60° C. for 1 min, and 95° C. for 15 sec to measure a melting curve). Quantitation was normalized to 18S rRNA expression level.
  • a pair of primers for mouse collagen I ⁇ 1 were 5′-GAACATCACCTACCACTGCA-3′(SEQ ID NO: 13) and 5′-GTTGGGATGGAGGGAGTTTA-3′ (SEQ ID NO: 14).
  • Forward and reverse primers for mouse r18S rRNA were 5′-CGA AAG CAT TTG CCA AGA AT-3′ (SEQ ID NO: 11) and 5′-AGT CGG CAT CGT TTA TGG TC-3′ (SEQ ID NO: 12), respectively.
  • Tables 3 to 12 and FIGS. 4 to 13 show inhibitory effects of the compounds of Examples 1 to 9 and Comparative Example 1 on collagen I ⁇ 1 expression in proximal tubular cells.
  • % inhibition means relative inhibition to 100% for the control and 0% for the group that was treated with hTGF- ⁇ 1 but not with any of the compounds of Examples or Comparative Example.
  • FIGS. 4 to 13 shows expression level ratios of collagen I ⁇ 1 (Col1 ⁇ ) to 18S rRNA (18S) (relative increase) for each group.
  • the compounds of the present invention inhibited the expression of the extracellular matrix, collagen I ⁇ 1 (Col1 ⁇ ), in proximal tubular cells.
  • the compounds of the present invention generally inhibited the expression of the extracellular matrix, collagen I ⁇ 1 (Col1 ⁇ ), in a concentration-dependent manner (except for the compound of Example 9).
  • the compound of Comparative Example decreased the expression level of the extracellular matrix, collagen I ⁇ 1 (Col1 ⁇ ).
  • the compounds of the present invention were found to more effectively inhibit the expression of the extracellular matrix, collagen I ⁇ 1 (Col1 ⁇ ), because their IC 50 values were at least three-fold lower than that of the compound of Comparative Example.
  • the compounds of the present invention can therefor suppress renal fibrosis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
US14/424,771 2012-08-27 2013-08-02 Composition for treating kidney disease comprising pyrazole derivative Active 2034-01-17 US10047067B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020120093936A KR101633957B1 (ko) 2012-08-27 2012-08-27 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
KR10-2012-0093936 2012-08-27
PCT/KR2013/006985 WO2014035070A1 (ko) 2012-08-27 2013-08-02 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
US20150218125A1 US20150218125A1 (en) 2015-08-06
US10047067B2 true US10047067B2 (en) 2018-08-14

Family

ID=50183832

Family Applications (1)

Application Number Title Priority Date Filing Date
US14/424,771 Active 2034-01-17 US10047067B2 (en) 2012-08-27 2013-08-02 Composition for treating kidney disease comprising pyrazole derivative

Country Status (9)

Country Link
US (1) US10047067B2 (enExample)
EP (1) EP2889032B1 (enExample)
JP (1) JP5974180B2 (enExample)
KR (1) KR101633957B1 (enExample)
CN (1) CN104755077B (enExample)
ES (1) ES2734264T3 (enExample)
PL (1) PL2889032T3 (enExample)
TR (1) TR201909923T4 (enExample)
WO (1) WO2014035070A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101826208B1 (ko) 2016-02-05 2018-02-06 경북대학교 산학협력단 뉴로펩타이드 y를 유효성분으로 포함하는, 신장질환의 예방 또는 치료용 약학적 조성물
KR101856444B1 (ko) * 2017-04-20 2018-05-10 압타바이오 주식회사 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물
KR101840702B1 (ko) * 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
WO2021101344A1 (ko) 2019-11-21 2021-05-27 삼진제약주식회사 안질환 예방 또는 치료용 점안 조성물
KR102277665B1 (ko) * 2020-02-05 2021-07-15 바이오그래핀 주식회사 그래핀 기반 신장 질환 치료용 조성물
US20230201179A1 (en) * 2020-04-08 2023-06-29 Aptabio Therapeutics Inc. Agent for treating contrast-induced acute kidney injury
KR102308991B1 (ko) * 2020-04-08 2021-10-06 압타바이오 주식회사 조영제 유발 급성 신부전 치료제
CN115427039B (zh) * 2020-04-13 2025-04-04 阿普塔生物治疗公司 包含吡唑衍生物的肺纤维化药物
KR102386097B1 (ko) * 2020-04-13 2022-04-14 압타바이오 주식회사 피라졸 유도체의 폐섬유증 치료제
JP2023553010A (ja) 2020-12-03 2023-12-20 バテル・メモリアル・インスティテュート 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法
KR102589130B1 (ko) * 2021-03-24 2023-10-13 삼진제약주식회사 N-옥소 피리딘 화합물 발생을 억제하는 안질환 예방 또는 치료용 점안 조성물
EP4320233A4 (en) 2021-04-07 2025-08-13 Battelle Memorial Institute RAPID DESIGN, BUILD, TEST, AND LEARNING TECHNOLOGIES TO IDENTIFY AND USE NON-VIRAL VECTORS
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems
CN119504599B (zh) * 2024-11-18 2025-09-26 安徽医科大学 一种用于治疗肾脏纤维化的吡唑类化合物及其应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175176A (en) 1990-07-24 1992-12-29 Bayer Aktiengesellschaft 1-[pyri(mi)dyl-(2)]-hydroxy-pyrazole microbicides
WO1993007138A1 (fr) 1991-10-08 1993-04-15 Nippon Soda Co., Ltd. Derive de pyrazole et bactericide utilisable en agriculture/horticulture contenant ce derive
KR20030027709A (ko) 2001-09-26 2003-04-07 가부시키가이샤 도쿄 웰드 외관검사장치
JP2003335672A (ja) 2002-05-20 2003-11-25 Ajinomoto Co Inc 線維化病変組織修復剤
KR20040094464A (ko) 2003-05-02 2004-11-10 학교법인 이화학당 피리디닐 피라졸 유도체
EP1900728A1 (en) 2005-05-30 2008-03-19 Genecare Research Institute Co., Ltd Pharmaceutical composition comprising pyrazolone derivative
EP2050745A1 (en) 2006-09-01 2009-04-22 Otsuka Chemical Co., Ltd. N-pyridylpiperidine compound, method for producing the same, and pest control agent
WO2009119987A2 (ko) * 2008-03-25 2009-10-01 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 골다공증 예방 및 치료용 조성물
KR20110025149A (ko) 2009-09-02 2011-03-09 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
US20120232117A1 (en) 2009-09-02 2012-09-13 Ewha University-Industry Collaboration Foundation Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175176A (en) 1990-07-24 1992-12-29 Bayer Aktiengesellschaft 1-[pyri(mi)dyl-(2)]-hydroxy-pyrazole microbicides
US5292744A (en) 1990-07-24 1994-03-08 Bayer Aktiengesellschaft 1-[pyri(mi)dyl-(2)]-5-hydroxy-pyrazole microbicides
WO1993007138A1 (fr) 1991-10-08 1993-04-15 Nippon Soda Co., Ltd. Derive de pyrazole et bactericide utilisable en agriculture/horticulture contenant ce derive
KR20030027709A (ko) 2001-09-26 2003-04-07 가부시키가이샤 도쿄 웰드 외관검사장치
JP2003335672A (ja) 2002-05-20 2003-11-25 Ajinomoto Co Inc 線維化病変組織修復剤
KR20040094464A (ko) 2003-05-02 2004-11-10 학교법인 이화학당 피리디닐 피라졸 유도체
EP1900728A1 (en) 2005-05-30 2008-03-19 Genecare Research Institute Co., Ltd Pharmaceutical composition comprising pyrazolone derivative
EP2050745A1 (en) 2006-09-01 2009-04-22 Otsuka Chemical Co., Ltd. N-pyridylpiperidine compound, method for producing the same, and pest control agent
WO2009119987A2 (ko) * 2008-03-25 2009-10-01 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 골다공증 예방 및 치료용 조성물
KR20110025149A (ko) 2009-09-02 2011-03-09 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
US20120232117A1 (en) 2009-09-02 2012-09-13 Ewha University-Industry Collaboration Foundation Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
US8637674B2 (en) 2009-09-02 2014-01-28 Ewha University-Industry Collaboration Foundation Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same

Non-Patent Citations (35)

* Cited by examiner, † Cited by third party
Title
Almansa et al., "Synthesis and Structure-Activity Relationship of a New Series of Potent AT1 Selective Angiotensin II Receptor Antagonists: 5-(Biphenyl-4-ylmethyl)pyrazoles," J. Med. Chem. 40:547-558, 1997.
Bae (KR Oct. 2011-0025149), copy with machine translation provided. Also cited as D1 on international search report. *
Boyle et al., "Osteoclast differentiation and activation," Nature 423:337-342, 2003.
CAPLUS, Accession No. 1994:106997, "Preparation of pyrazole derivatives and agrochemical fungicides," 30 pages.
CAPLUS, Accession No. 1995:339446, "Preparation of pyrazole derivatives as agricultural and horticultural fungicides," 4 pages.
CAS Registry No. 1187849-40-6, "3H-Pyrazol-3-one, 2,4-dihydro-5-(3-methoxyphenyl)-2-(2-pyridinyl)-C15H13N3O2," Apr. 2, 2014, 10 pages.
CAS Registry No. 1187849-40-6, "3H-Pyrazol-3-one, 2,4-dihydro-5-(3-methoxyphenyl)-2-(2-pyridinyl)—C15H13N3O2," Apr. 2, 2014, 10 pages.
CAS Registry No. 1270043-84-9, "1H-Pyrazol-5-ol, 3-[(2-naphthalenylozy)methyl]-1-(2-pyridinyl)-C19H15N3O2," Sep. 2, 2015, 29 pages.
CAS Registry No. 1270043-84-9, "1H-Pyrazol-5-ol, 3-[(2-naphthalenylozy)methyl]-1-(2-pyridinyl)—C19H15N3O2," Sep. 2, 2015, 29 pages.
CAS Registry No. 1270083-83-4, "1H-Pyrazol-5-ol, 3-(4-bromophenyl)-1-(2-pyridinyl)-C14H10BR N3 O," Apr. 2, 2014, 22 pages.
CAS Registry No. 1270083-83-4, "1H-Pyrazol-5-ol, 3-(4-bromophenyl)-1-(2-pyridinyl)—C14H10BR N3 O," Apr. 2, 2014, 22 pages.
CAS Registry No. 1270083-87-8, "1H-Pyrazol-5-ol, 3-(3-iodophenyl)-1-(2-pyridinyl)-C14H10I N3 O," Sep. 16, 2016, 33 pages.
CAS Registry No. 1270083-87-8, "1H-Pyrazol-5-ol, 3-(3-iodophenyl)-1-(2-pyridinyl)—C14H10I N3 O," Sep. 16, 2016, 33 pages.
CAS Registry No. 1270084-03-1, "1H-Pyrazol-5-ol, 3-(4-bromophenyl)-1-(2-pyridinyl)-, 5-acetate C16H12Br N3O2," Apr. 2, 2014, 22 pages.
CAS Registry No. 1270084-50-8, "1H-Pyrazol-5-ol, 3-[4-(1,3-benzodioxol-5-yl)phenyl]-1-(2-pyridinyl)-C21H15N3O3," Apr. 2, 2014, 22 pages.
CAS Registry No. 1270084-50-8, "1H-Pyrazol-5-ol, 3-[4-(1,3-benzodioxol-5-yl)phenyl]-1-(2-pyridinyl)—C21H15N3O3," Apr. 2, 2014, 22 pages.
CAS Registry No. 1270084-88-2, "1H-Pyrazol-5-ol, 3-[1,1′-biphenyl]-4-yl-1-(2-pyrimidinyl)-C19H14N4 O," Apr. 2, 2014, 19 pages.
CAS Registry No. 1270084-88-2, "1H-Pyrazol-5-ol, 3-[1,1′-biphenyl]-4-yl-1-(2-pyrimidinyl)—C19H14N4 O," Apr. 2, 2014, 19 pages.
CAS Registry No. 1270084-92-8, "1H-Pyrazol-5-ol, 3-phenyl-4-propyl-1-(2-pyridinyl)-C17H17N3 O," Sep. 21, 2016, 24 pages.
CAS Registry No. 1270084-92-8, "1H-Pyrazol-5-ol, 3-phenyl-4-propyl-1-(2-pyridinyl)—C17H17N3 O," Sep. 21, 2016, 24 pages.
Darden et al., "Osteoclastic Superoxide Production and Bone Resorption: Stimulation and Inhibition by Modulators of NADPH Oxidase," Journal of Bone and Mineral Research 11(5):671-675, 1996.
Extended European Search Report, dated Feb. 5, 2016, for corresponding European Application No. 13834243.1-1453 / 288032, 12 pages.
Fraser et al., "Hydrogen Peroxide, But Not Superoxide, Stimulates Bone Resorption in Mouse Calvariae," Bone 19(3):223-226, 1996.
Li et al., "Role of NADPH oxidase in diabetic nephropathy," International Journal of Internal Medicine 36(2):93-97, 2009. (with Partial English Translation).
Mattos et al., Disease Activity in systemic lupus erythematosus patients with end-stage renal disease: systemic review of the literature, 2012, Clinc Rheumatol, 31, 897-905. *
Office Action, dated Oct. 9, 2016, for Chinese Application No. 201380056244.5, 13 pages. (with English Translation).
Oikawa et al., "Meldrum's Acid in Organic Synthesis. 2. A General and Versatile Synthesis of β-Keto Esters," J. Org. Chem. 43(10):2087-2088, 1978.
Park et al., "Identification of antitumor activity of pyrazole oxime ethers," Bioorganic & Medicinal Chemistry Letters 15:3307-3312, 2005.
Park et al., "Introduction of N-Containing Heterocycles into Pyrazole by Nucleophilic Aromatic Substitution," Synthetic Communications 34(9):1541-1550, 2004.
Reidy et al., Molecular mechanisms of diabetic kidney disease, 2014, The Journal of Clinical Investigation, vol. 124, No. 6, pp. 2333-2340. *
Sawyer et al., "Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-β Type I Receptor Kinase Domain," J. Med. Chem. 46(19):3953-3956, Sep. 2003.
Wilson, Polycystic Kidney Disease, 2004, N Engl J Med, 350:2, pp. 151-164. *
Yang et al., "A New Superoxide-generating Oxidase in Murine Osteoclasts," The Journal of Biological Chemistry 276(8):5452-5458, 2001.
Yang et al., "Nicotinamide Adenine Dinucleotide Phosphate Oxidase in the Formation of Superoxide in Osteoclasts," Calcif Tissue Int 63:346-350, 1998.
Yu-Feng et al., "Expression of renal nuclear factor-kappaB, transforming growth factor-beta and fibronectin of rats exposed to lead," Chinese Journal of Industrial Hygiene and Occupational Diseases 24(3):139-142, 2006, Abstract Only, 1 page.

Also Published As

Publication number Publication date
CN104755077A (zh) 2015-07-01
WO2014035070A1 (ko) 2014-03-06
ES2734264T3 (es) 2019-12-05
JP5974180B2 (ja) 2016-08-23
KR101633957B1 (ko) 2016-06-27
JP2015531774A (ja) 2015-11-05
CN104755077B (zh) 2018-05-15
KR20140027833A (ko) 2014-03-07
EP2889032A1 (en) 2015-07-01
TR201909923T4 (tr) 2019-07-22
EP2889032A4 (en) 2016-03-09
US20150218125A1 (en) 2015-08-06
EP2889032B1 (en) 2019-05-08
PL2889032T3 (pl) 2019-09-30

Similar Documents

Publication Publication Date Title
US10047067B2 (en) Composition for treating kidney disease comprising pyrazole derivative
US10966969B2 (en) Therapeutic agent for liver diseases
KR101630432B1 (ko) 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 암 예방 또는 치료용 약학 조성물
EP4105206A1 (en) Novel pyrazole derivative
CN102724978A (zh) 用于治疗或预防炎症或能量代谢/产生相关疾病的PPARδ配体的用途
KR101302315B1 (ko) 피라졸 유도체를 포함하는 호흡기 질환 예방 및 치료용 조성물
EP2682392A2 (en) Pyrazole derivatives, preparation method thereof, and composition for preventing and treating osteoporosis containing same
CN116392481A (zh) As252424在制备用于防治铁死亡相关疾病药物中的应用
US20040097539A1 (en) Hsp inductor
WO2017155053A1 (ja) 非アルコール性脂肪性肝疾患／非アルコール性脂肪性肝炎の治療剤
WO2002006249A1 (en) Method for producing 1-substituted-1,2,3-triazole derivative
JP7085994B2 (ja) 線維症疾患の治療及び／又は予防用アミノナフトキノン化合物
CN104546835B (zh) 3-(苯甲酰苯基)丙酸衍生物在治疗连接蛋白cx31介导的皮肤病中的应用
KR101683362B1 (ko) 소양증 개선 활성을 갖는 벤즈옥사졸 유도체
CN106916104B (zh) 用于治疗结肠炎的药物
CN115974719B (zh) 化合物、包括所述化合物的药物组合物及其用途
CN107709324B (zh) 黄嘌呤衍生物
WO2009003307A1 (fr) Dérivés de phtiobuzonum et préparation, composition pharmaceutique et utilisation de ceux-ci
CN111303161B (zh) 嘧啶并氮杂环类化合物及其用途
WO2025252099A1 (zh) 一种吡咯并六元芳环化合物及其制备方法和应用

Legal Events

Date Code Title Description
AS Assignment

Owner name: EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAE, YUN SOO;HA, HUN JOO;LEE, KEE IN;AND OTHERS;SIGNING DATES FROM 20150430 TO 20150519;REEL/FRAME:035877/0229

FEPP Fee payment procedure

Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PTGR); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4